Minivnutrition
Later, he explored using these particles to suppress the cells driving the disease.
In 2001, immunologist Pere Santamaria developed a method using iron oxide nanoparticles to track immune cells involved in diabetes.
Researchers globally aim to rein in cells causing autoimmune disorders, seeking ways to restore immune tolerance.
Now, after over two decades, his nanoparticle therapy is nearing human trials.
Liver-centric approaches, targeting cellular debris, and engineering regulatory T cells show promise.
Strategies involve deprogramming rogue cells or selectively eliminating them, with companies like Parvus Therapeutics and Anokion preparing for clinical trials.
B cells, often overlooked, emerge as promising targets. Approaches involving B-cell depletion and precise targeting with therapies like CAAR T cells show potential.
CAR-T cell therapies exhibit remarkable results, inducing remission in lupus and systemic sclerosis patients.
Researchers stress understanding underlying mechanisms before advancing to clinical trials to improve the chances of success.
Despite optimism, caution prevails, as past attempts at immune tolerance fell short in clinical testing.